Research
Hormonal
Circulating very-long-chain saturated fatty acids (VLCSFAs) in erythrocytes are NOT significantly associated with a reduced risk of incident coronary heart disease (CHD) after multivariate adjustment.
Unlike plasma levels, erythrocyte levels of these specific fatty acids do not show a clear protective effect against heart disease in this study. This highlights that the location of the fatty acid (plasma vs. cell membrane) matters for its health impact.
GoodRefutesMEDIUM confidence
For VLCSFAs in erythrocytes, a nonsignificant inverse trend with CHD risk was observed (pooled hazard ratio, 0.66; 95% confidence interval, 0.41–1.06, comparing extreme quintiles; Ptrend=0.16).
Why this rating
Same rigorous cohort design as the primary finding, but the result was non-significant.
Source
Circulating Very-Long-Chain Saturated Fatty Acids and Incident Coronary Heart Disease in US Men and Women
Vasanti Malik et al. · Circulation · 2015
DOI 10.1161/circulationaha.114.014911
cohort · n=2027Cited 92×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Higher circulating levels of plasma very-long-chain saturated fatty acids (VLCSFAs: C20:0, C22:0, C24:0) are associated with a significantly lower risk of incident coronary heart disease (CHD) in US men and women.Good
- Circulating very-long-chain saturated fatty acids (VLCSFAs) in plasma are associated with favorable cardiovascular risk markers, including higher HDL-C, lower triglycerides, and higher adiponectin.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →